Spdr S&p Biotech Etf ETF News

Pettinga Financial Advisors LLC purchased a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 5,642 shares of the exchange traded funds stock, valued at approximately $709,000. Other institutional investors and hedge funds also recently bought []

Here are three stocks sure to pique the interest of that special someone.

A Screaming Dislocation - "We Must Raise Cash" On Any Rally From Here Excerpted from Larry McDonald''s Bear Traps Report, A Colossal Rotation Has Begun Into Value As we can see below, Value has been out-performing Growth for more than 16 months on an equal-weight basis. It is the highest compliment when the Street picks up on an investment thesis months after we started to walk down this trail. This week - Goldman Sachs and Bank of America focused on the carnage inside long duration (Nasdaq) equities. Goldman´s Tony Pasquariello noted: a screaming dislocation has emerged between long-duration equities (which have been falling apart - ARK Names, Software, long duration cash flows) and long duration itself (the yield on the 30 year long bond is near YTD lows). Elements of capitulation are starting to accumulate and there are clear footprints of major risk reduction. We have seen two 80% + surges in the VIX since September 1, immense volume on intraday selloffs punctuated with a string of MOC sell imbalances.

Despite economic uncertainty, big biopharma companies have tons of cash to spend on deals.

Michael Yee, Jefferies, on whether there's more M&A to come in the biotech space. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Steve Grasso, Pete Najarian and Karen Finerman.

Greenwood Capital Associates LLC decreased its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 14.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,572 shares of the exchange traded fund’s stock after selling 784 shares during the quarter. Greenwood Capital Associates […]

Merit Financial Group LLC lowered its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 19.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,048 shares of the exchange traded fund’s stock after selling 11,632 shares during the period. SPDR S&P Biotech ETF […]

Sector ETF report for PBE

Phoenix Holdings Ltd. purchased a new stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 567,650 shares of the exchange traded funds stock, valued at approximately $71,359,000. SPDR S&P Biotech ETF comprises about 1.2% of Phoenix []

The Market is having crazy volatility, Does that mean retreat? No. What about inflation, What about soaring interest rates? Bad news? That isn't the message of the market.

The Market is having crazy volatility, Does that mean retreat? No. What about inflation, What about soaring interest rates? Bad news? That isn't the message of the market.

Every week we talk to the most interesting managers and highlight the most timely ETF news, from new launches to inflows and performance.

Sector rotation and rolling corrections continue, further complicating the investment backdrop. As the Fed starts to “taper”, no one can claim they were shocked. Read more here.